CTOs on the Move

Biofourmis

www.biofourmis.com

 
Biofourmis is a fast-growing global health IT start-up founded in Singapore that augments personalized patient care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. The company discovers, develops and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers. Biofourmis has built Biovitals™, a highly sophisticated personalized artificial intelligence (AI)-powered health analytics platform that predicts clinical exacerbation days in advance before a critical event. Biovitals™ is the backbone of the company`s Digital Therapeutics product pipeline, which spans ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Milan Shah
Chief Technology Officer Profile
Jaydev Thakkar
Chief Operating Officer Profile

Funding

Biofourmis raised $100M on 09/03/2020

Similar Companies

Nerium International

At Nerium International, making people better means establishing a business that can bring real change to your life, your skin, and your personal development.   Through our partnership with Nerium SkinCare, a division of Nerium Biotechnology, Inc., Nerium International markets breakthrough products validated by real science.   These age-defying skincare products are distributed exclusively by our Independent Brand Partners.

SutroVax

SutroVax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. SutroVax`s lead product candidate is a pneumococcal conjugate vaccine (PCV) that is designed to prevent invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. SutroVax`s broad-spectrum PCV is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. The current mainstay vaccine only covers approximately 40% of the circulating strains causing IPD yet generates $6B in annual sales. SutroVax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum PCV compared head-to-head to current vaccines using well accepted immunological endpoints. In addition to its lead PCV product candidate, the Company also has a promising early-stage pipeline addressing other important disease areas. SutroVax`s conjugate vaccines are developed utilizing the Company`s exclusive rights to Sutro Biopharma`s Xpress CF Platform, a cell-free protein synthesis technology. SutroVax closed its $85M Series C round in May of 2018 and is financed by a world-class syndicate of private equity, venture capital and corporate venture investors with over $170M in capital raised since 2015.

AgriMetis

AgriMetis discovers, develops, and delivers innovative crop protection products. Our scientific approach is multidisciplinary and integrated which allows AgriMetis to exploit areas of chemical space and production routes that are inaccessible to others. The AgriMetis platform delivers rapid, efficient, and optimal solutions to challenges in crop protection by bringing innovative products and their production processes to the market faster for the $56 billion agricultural chemical industry.

Borregaard head office

Borregaard head office is a Norway, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UVJ technology

UVJ technology is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.